Lupin Limited said China’s National Medical Products Administration has approved its abbreviated new drug application for Oseltamivir Phosphate oral suspension, clearing the way for the company’s first product launch in the Chinese market. The antiviral, developed in partnership with Yabao Pharmaceuticals, will be introduced as a 6 mg/mL oral suspension with a focus on expanding access for pediatric patients, reflecting Yabao’s established position in China’s pediatric medicine segment.
Oseltamivir Phosphate oral suspension (6 mg base/mL) is indicated for the treatment of influenza A and B in patients 2 weeks of age and older, and for the prevention of influenza A and B in individuals 1 year of age and older. Lupin said the launch will support its broader strategy to grow its global footprint while providing high-quality, affordable medicines to patients and children in need.
“We are delighted that we have received approval for Oseltamivir Oral Suspension in China. This is a strategic step in our entry into one of the world’s largest pharmaceutical markets,” said Fabrice Egros, president, corporate development at Lupin. He said the approval reflects a shared commitment with Yabao to expand access to affordable therapies, particularly in pediatric care, and added that Lupin looks forward to strengthening its presence in China through the partnership.
Wei Ren, president of Yabao, called the approval a key milestone in the companies’ collaboration and said it reinforces Yabao’s focus on quality pediatric medicines. He noted that the partners plan to further expand their research and development portfolio for pediatric and adult chronic disease drugs as they advance their respective businesses in China.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!